AR065767A1 - Derivados de fenilquinazolinas,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos y usos para el tratamiento del cancer. - Google Patents
Derivados de fenilquinazolinas,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos y usos para el tratamiento del cancer.Info
- Publication number
- AR065767A1 AR065767A1 ARP080101080A ARP080101080A AR065767A1 AR 065767 A1 AR065767 A1 AR 065767A1 AR P080101080 A ARP080101080 A AR P080101080A AR P080101080 A ARP080101080 A AR P080101080A AR 065767 A1 AR065767 A1 AR 065767A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- substituted
- hydrogen
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1 Un compuesto de la Formula 1 o un isomero individual del mismo, donde el compuesto está optativamente en forma de sal aceptable para uso farmacéutico, hidrato, solvato o una combinacion de los mismos, donde R1 es alquilo,cicloalquilo, fenilo, o heteroarilo donde el cicloalquilo, fenilo y heteroarilo están optativamente sustituidos con 1, 2 o 3 R6; R2 y R3 junto con el pirimidinilo al cual están unidos forman un quinazolinilo optativamente sustituido en lasposiciones 5, 6, 7 y 8 con uno o dos grupos seleccionados independientemente de alquilo, alcoxi, halo, hidroxi, heterocicloalquilalquiloxi, heterocicloalquilo y heterocicloalquilo sustituido con alquilo; o R2 y R3 junto con el pirimidinilo al cualestán unidos forman un pirido[3,2-d]pirimidinilo, pirido[4,3-d]pirimidinilo, pirido[3,4-d]pirimidinilo, o pirido[2,3-d]pirimidinilo, cada uno de los cuales está optativamente sustituido en un átomo de carbono, en las posiciones 5, 6, 7 y 8, con unoo dos grupos seleccionados independientemente entre alquilo, alcoxi, halo, hidroxi, heterocicloalquilalquiloxi, heterocicloalquilo y heterocicloalquilo sustituido con alquilo; o R2 y R3 junto con el pirimidinilo al cual están unidos forman un 6,7-dihidro-5H-ciclopenta[d]pirimidinilo, 5,6,7,8-tetrahidroquinazolinilo, o 6,7,8,9-tetrahidro- 5H-ciclohepta[d]pirimidinilo; o R2 y R3 junto con el pirimidinilo al cual están unidos forman un 5,6,7,8-tetrahidropirido[3,2-d]pirimidinilo, 5,6,7,8-tetrahidropirido[4 ,3-d]pirimidinilo, 5,6,7,8-tetrahidropirido[3 ,4-d]pirimidinilo, o 5,6,7,8-tetrahidropirido[2,3-d]pirimidinilo, cada uno de los cuales está optativamente sustituido en las posiciones 5, 6, 7 y 8 con uno o dos grupos seleccionadosindependientemente entre alquilo, alcoxicarbonilo, benciloxicarbonilo y fenilalquilo optativamente sustituido; cada R6, en caso de estar presente R6, es independientemente seleccionado entre alquilo, alcoxi, amino, alquilamino, dialquilamino, halo,haloalquilo, haloalcoxi, halofenilo, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, hidroxialquilo, alcoxicarbonilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, aminoalquilamino, alquilaminoalquilamino,dialquilaminoalquilamino, alquiloxialquilamino, heterocicloalquilo y heterocicloalquilalquilo; donde el heterocicloalquilo, solo o como parte del heterocicloalquilalquilo, está optativamente sustituido con alquilo o alcoxicarbonilo; R40 es hidrogenoo alquilo; R50 es seleccionado entre el grupo de formulas 2; n1 es 0, 1,o 2; cada R5, en caso de estar presente R5, es independientemente alquilo, hidroxi, alcoxi, amino, alquilamino, dialquilamino, halo, nitro, heterocicloalquilo,heterocicloalquilamino, o heterocicloalquilalquiloxi; donde cada heterocicloalquilo, solo o como parte de otro grupo presente en R5, está independientemente optativamente sustituido con alquilo o alcoxicarbonilo; R4a es hidrogeno o alquilo; R4 esheteroarilo sustituido con un R8 y está sustituido además con 1 o 2 R8a; R4 es fenilo sustituido con un R29 y está sustituido además con 1 o 2 R9a; R4 es cicloalquilo optativamente sustituido con uno o dos grupos seleccionados independientementeentre alquilo, hidroxi, alcoxi, amino, alquilamino y dialquilamino; o R4 es heterocicloalquilo optativamente sustituido con alquilo o alcoxicarbonilo; R17 es cicloalquilo, heterocicloalquilo (optativamente sustituido con uno o dos gruposseleccionados entre alquilo y alcoxicarbonilo), fenilalquilamino, fenilalquilo, o fenilo; donde cada fenilo, solo o como parte de un grupo presente en R17, está sustituido con 1, 2 o 3 R9a; R18 es hidrogeno, halo, o alquilo; R18a es hidrogeno oalquilo; R18b es heteroarilo sustituido con 1, 2 o 3 R8a, o R18b es fenilo sustituido con 1, 2 o 3 R9a; R19 es fenilo sustituido con 1, 2 o 3 R9a, o R19 es heteroarilo sustituido con 1, 2 o 3 R8a; R20 es hidrogeno, alquilo, alquilcarbonilo,alquilsulfonilo, o alcoxicarbonilo; R20 es hidrogeno o alquilo; R20b es heteroarilo sustituido con 1, 2 o 3 R8a, o R20b es fenilo sustituido con 1, 2 o 3 R9a; R21 es fenilo sustituido con 1, 2 o 3 R9a, o R21 es heteroarilo sustituido con 1, 2 o 3R8a, o R21 es heterocicloalquilo optativamente sustituido con alquilo o alcoxicarbonilo; R22 es fenilo sustituido con 1, 2 o 3 R9a, o R22 es heteroarilo sustituido con 1, 2 o 3 R8a; cada R8 es independientemente alquilo, cicloalquilo,fenílalquiloxialquilo, o R9b; cada R8 es independientemente hidrogeno, halo, o R8; cada R9 es independientemente hidrogeno, R9b, o R9c; R29 es R9b o R9c siempre que R29 sea R9b cuando R1 es fenilo no sustituido y cuando R1 es fenilo sustituido con1, 2 o 3 R6 seleccionado independientemente entre alquilo, halo, alcoxi, hidroxialquilo, aminoalquilo y alcoxicarbonilo; cada R9b, cuando R9b está presente, es independientemente amino, alquilamino, dialquilamino, heterocicloalquilo optativamentesustituido, heterocicloalquilalquiloxi optativamente sustituido, aminoalquiloxi, alquilaminoalquiloxi, dialquilaminoalquiloxi, heteroarilo optativamente sustituido, ciano, -C(O)R14, CR14a(=NR14b), -C(=NR24)R24a, -S(O)2NR13R13a, -NR23C(O)R23a -C(O)NR12R12a, o alquilo sustituido con uno o dos R11; cada R9C, cuando R9C está presente, es independientemente alquilo, haloalquilo, hidroxialquilo, halo, hidroxi, alcoxi, ciano, nitro, o fenilcarbonilo; cada R11 es independientemente seleccionadoentre hidroxi, -NR15R15a, heteroarilo optativamente sustituido, heterocicloalquilo optativamente sustituido y cicloalquilo optativamente sustituido; R12 es hidrogeno o alquilo y R12a es hidrogeno, hidroxi, alcoxi, alquilo, aminoalquilo,alquilaminoalquilo, dialquilaminoalquilo, hidroxialquilo, heterocicloalquilo optativamente sustituido, heterocicloalquilalquilo optativamente sustituido, o heteroarilo optativamente sustituido; o R12 y R12a junto con el nitrogeno al cual estánunidos forman un heterocicloalquilo optativamente sustituido con 1, 2 o 3 grupos seleccionados independientemente entre alquilo, hidroxialquilo, haloalquilo, alquilcarbonilo, alcoxicarbonilo, cicloalquilo optativamente sustituido, cicloalquilalquilooptativamente sustituido, heteroarilo optativamente sustituido, heteroarilalquilo optativamente sustituido, fenilo optativamente sustituido y fenilalquilo optativamente sustituido; R13 es hidrogeno o alquilo; R13a es alquilo, aminoalquilo,alquilaminoalquilo, o dialquilaminoalquilo; cada R14 es independientemente hidrogeno, alquilo, hidroxi, alcoxi, heteroarilalquilo optativamente sustituido, o heterocicloalquilalquilo optativamente sustituido; cada R14a es hidrogeno o alquilo; R14bes alcoxi, amino, alquilamino, dialquilamino, o heterocicloalquilo optativamente sustituido; R15 es hidrogeno, alquilo, alcoxialquilo, hidroxialquilo, o haloalquilo; R15a es hidrogeno, alquilo, alcoxialquilo, haloalquilo, hidroxialquilo,carboxialquilo, aminocarbonilalquilo, alquilaminocarbonilalquilo, dialquilaminocarbonilalquilo, cicloalquilo optativamente sustituido, o fenilalquilo optativamente sustituido; R23 es hidrogeno o alquilo; R23a es hidrogeno, alquilo, aminoalquilo,alquilaminoalquilo, dialquilaminoalquilo, o heterocicloalquilalquilo optativamente sustituido; R24 es hidrogeno o alquilo, hidroxi, o alcoxi; y R24a es hidroxi, alcoxi, amino, alquilamino, o dialquilamino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91816007P | 2007-03-14 | 2007-03-14 | |
US96261707P | 2007-07-30 | 2007-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065767A1 true AR065767A1 (es) | 2009-07-01 |
Family
ID=39760053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101080A AR065767A1 (es) | 2007-03-14 | 2008-03-14 | Derivados de fenilquinazolinas,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos y usos para el tratamiento del cancer. |
Country Status (18)
Country | Link |
---|---|
US (3) | US8222263B2 (es) |
EP (2) | EP2527330A1 (es) |
JP (1) | JP5577104B2 (es) |
KR (1) | KR20090130051A (es) |
CN (1) | CN101679308B (es) |
AR (1) | AR065767A1 (es) |
AU (1) | AU2008224941C1 (es) |
BR (1) | BRPI0808772A2 (es) |
CA (1) | CA2680796A1 (es) |
CO (1) | CO6231031A2 (es) |
EA (1) | EA018441B1 (es) |
GE (1) | GEP20135925B (es) |
IL (1) | IL200603A (es) |
MX (1) | MX2009009786A (es) |
NZ (2) | NZ579480A (es) |
SG (1) | SG179418A1 (es) |
TW (1) | TWI430798B (es) |
WO (1) | WO2008112913A1 (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101573358B (zh) * | 2006-09-15 | 2012-05-30 | 辉瑞产品公司 | 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途 |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
EA018441B1 (ru) | 2007-03-14 | 2013-08-30 | ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи | Ингибиторы пути хеджхога |
US20100144756A1 (en) * | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
CN104059124A (zh) | 2007-12-27 | 2014-09-24 | 无限药品股份有限公司 | 立体选择性还原的方法 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587719A (en) * | 2008-02-26 | 2012-04-27 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
CA2765053C (en) * | 2009-06-09 | 2015-08-18 | California Capital Equity, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
WO2011017551A1 (en) | 2009-08-05 | 2011-02-10 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
HUE029094T2 (hu) * | 2009-08-25 | 2017-02-28 | Abraxis Bioscience Llc | Kombinációs terápia egy taxánt és egy albumint tartalmazó nanorészecskéket magába foglaló készítménnyel |
WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2576532B1 (en) * | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
EP2611795B1 (en) * | 2010-09-01 | 2016-05-04 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
WO2012037217A1 (en) | 2010-09-14 | 2012-03-22 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CA3061239A1 (en) | 2011-02-28 | 2012-09-07 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
US8729079B2 (en) | 2011-08-23 | 2014-05-20 | Endo Pharmaceuticals Inc. | Pyrimido-pyridazinone compounds and methods of use thereof |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
US20140309184A1 (en) * | 2011-09-21 | 2014-10-16 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
JP6106685B2 (ja) * | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
CA2864085C (en) * | 2012-02-08 | 2021-11-23 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
CA2890002A1 (en) * | 2012-11-05 | 2014-05-08 | Nant Holdings Ip, Llc | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway |
AU2013352256A1 (en) | 2012-11-29 | 2015-06-18 | Strasspharma, Llc | Methods of modulating follicle stimulating hormone activity |
CN103040824B (zh) * | 2013-01-17 | 2015-05-27 | 四川大学 | 信号通路抑制剂及其制备方法和用途 |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
EP2970194A1 (en) | 2013-03-15 | 2016-01-20 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CN105121415B (zh) | 2013-03-15 | 2018-10-12 | 生物马林药物股份有限公司 | Hdac抑制剂 |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
CN104177363B (zh) * | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
BR112015029969A2 (pt) | 2013-05-30 | 2017-07-25 | Infinity Pharmaceuticals Inc | tratamento de câncer usando moduladores de isoformas quinase pi3 |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
NZ719185A (en) | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
CA2943100C (en) | 2014-03-24 | 2017-04-04 | Hao Wu | Quinoline derivatives as smo inhibitors |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
CN104230853B (zh) * | 2014-08-18 | 2016-04-13 | 湖南华腾制药有限公司 | 一种(对甲苯基)甲胺-n-乙基吗啉盐酸盐的制备方法 |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CA2976973A1 (en) * | 2015-02-20 | 2016-08-25 | Bayer Pharma Aktiengesellschaft | N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA2988289C (en) | 2015-06-04 | 2023-12-05 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
WO2017139497A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018048746A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3544685B1 (en) | 2016-11-22 | 2023-01-04 | Development Center for Biotechnology | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof |
EP3615032A4 (en) | 2017-04-28 | 2020-12-23 | Asana BioSciences, LLC | FORMULATIONS, PROCEDURES, KITS AND DOSING FORMS FOR TREATMENT OF ATOPIC DERMATITIS AND IMPROVED STABILITY OF AN ACTIVE INGREDIENT |
CN107082765A (zh) * | 2017-06-07 | 2017-08-22 | 常州大学 | 一种2‑氯‑4‑苯基喹唑啉的合成方法 |
AU2018329840A1 (en) | 2017-09-07 | 2020-03-19 | Augusta University Research Institute, Inc. | Specific Akt3 activator and uses thereof |
ES2944547T3 (es) * | 2017-11-15 | 2023-06-22 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
CN115998742A (zh) * | 2021-10-21 | 2023-04-25 | 澳门大学 | 一种bms-833923及其衍生物的应用及药物 |
CN116621722A (zh) * | 2023-07-14 | 2023-08-22 | 甘肃帝邦升防水材料科技有限公司 | 超耐候柔性tpo自粘防水卷材及其制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
US6849634B2 (en) | 2000-12-21 | 2005-02-01 | Icagen | Potassium channel inhibitors |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
US7276502B2 (en) | 2003-03-25 | 2007-10-02 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
WO2004087698A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
DE602004008762T2 (de) * | 2003-04-30 | 2008-06-12 | The Institutes for Pharmaceutical Discovery, LLC, Branford | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
US8067608B2 (en) * | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
JP4903133B2 (ja) * | 2004-04-30 | 2012-03-28 | ジェネンテック,インコーポレイティド | ヘッジホッグシグナル伝達のキノキサリン阻害剤 |
UA96565C2 (ru) * | 2004-09-02 | 2011-11-25 | Дженентек, Инк. | Пиридильные ингибиторы хеджхоговской передачи сигнала |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
EP1903045A1 (en) | 2005-05-27 | 2008-03-26 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine derivative |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
WO2007147109A2 (en) * | 2006-06-16 | 2007-12-21 | Glaxo Group Limited | Novel compounds |
EP2034838A4 (en) * | 2006-06-16 | 2012-01-04 | Glaxo Group Ltd | NOVEL CONNECTIONS |
EA018441B1 (ru) | 2007-03-14 | 2013-08-30 | ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи | Ингибиторы пути хеджхога |
-
2008
- 2008-03-13 EA EA200970856A patent/EA018441B1/ru not_active IP Right Cessation
- 2008-03-13 NZ NZ579480A patent/NZ579480A/en unknown
- 2008-03-13 CA CA002680796A patent/CA2680796A1/en not_active Abandoned
- 2008-03-13 KR KR1020097021413A patent/KR20090130051A/ko not_active Application Discontinuation
- 2008-03-13 EP EP12180902A patent/EP2527330A1/en not_active Withdrawn
- 2008-03-13 NZ NZ598251A patent/NZ598251A/xx not_active IP Right Cessation
- 2008-03-13 CN CN200880015660.XA patent/CN101679308B/zh not_active Expired - Fee Related
- 2008-03-13 EP EP08732145A patent/EP2134695A4/en not_active Withdrawn
- 2008-03-13 WO PCT/US2008/056883 patent/WO2008112913A1/en active Application Filing
- 2008-03-13 BR BRPI0808772-5A patent/BRPI0808772A2/pt not_active IP Right Cessation
- 2008-03-13 MX MX2009009786A patent/MX2009009786A/es active IP Right Grant
- 2008-03-13 JP JP2009553783A patent/JP5577104B2/ja not_active Expired - Fee Related
- 2008-03-13 GE GEAP200811506A patent/GEP20135925B/en unknown
- 2008-03-13 AU AU2008224941A patent/AU2008224941C1/en not_active Ceased
- 2008-03-13 SG SG2012014213A patent/SG179418A1/en unknown
- 2008-03-14 TW TW097109202A patent/TWI430798B/zh not_active IP Right Cessation
- 2008-03-14 US US12/049,225 patent/US8222263B2/en not_active Expired - Fee Related
- 2008-03-14 AR ARP080101080A patent/AR065767A1/es not_active Application Discontinuation
-
2009
- 2009-08-27 IL IL200603A patent/IL200603A/en not_active IP Right Cessation
- 2009-10-13 CO CO09113466A patent/CO6231031A2/es active IP Right Grant
-
2012
- 2012-06-04 US US13/487,559 patent/US8796294B2/en active Active
- 2012-06-04 US US13/487,594 patent/US8754092B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2009009786A (es) | 2009-09-24 |
CO6231031A2 (es) | 2010-12-20 |
JP2010521487A (ja) | 2010-06-24 |
AU2008224941A1 (en) | 2008-09-18 |
CN101679308B (zh) | 2014-05-07 |
TWI430798B (zh) | 2014-03-21 |
NZ579480A (en) | 2012-03-30 |
EA200970856A1 (ru) | 2010-04-30 |
EP2527330A1 (en) | 2012-11-28 |
EP2134695A4 (en) | 2011-05-25 |
CN101679308A (zh) | 2010-03-24 |
US8222263B2 (en) | 2012-07-17 |
US20120245139A1 (en) | 2012-09-27 |
KR20090130051A (ko) | 2009-12-17 |
US8796294B2 (en) | 2014-08-05 |
SG179418A1 (en) | 2012-04-27 |
US20120238570A1 (en) | 2012-09-20 |
BRPI0808772A2 (pt) | 2014-08-12 |
EA018441B1 (ru) | 2013-08-30 |
US8754092B2 (en) | 2014-06-17 |
GEP20135925B (en) | 2013-10-10 |
US20090105211A1 (en) | 2009-04-23 |
AU2008224941B2 (en) | 2012-12-20 |
CA2680796A1 (en) | 2008-09-18 |
IL200603A (en) | 2014-08-31 |
IL200603A0 (en) | 2010-05-17 |
EP2134695A1 (en) | 2009-12-23 |
AU2008224941C1 (en) | 2013-06-27 |
NZ598251A (en) | 2013-06-28 |
WO2008112913A1 (en) | 2008-09-18 |
JP5577104B2 (ja) | 2014-08-20 |
TW200843777A (en) | 2008-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065767A1 (es) | Derivados de fenilquinazolinas,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos y usos para el tratamiento del cancer. | |
GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
RU2018121499A (ru) | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 | |
WO2008021928A3 (en) | Hepatitis c virus inhibitors | |
HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
UA95976C2 (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
EA027280B1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
MX2007005155A (es) | Nuevos derivados de aminopiridina que tienen accion inhibidora selectiva de la aurora a. | |
AR050969A1 (es) | 5-heterociclil pirimidinas inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos | |
AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
MD20140023A2 (ro) | Derivaţi de pirolpirimidină şi purină | |
WO2008076779A3 (en) | 2-(piperidin-4-yl0xy)pyrimidin-4-amine derivatives as deoxycytidine kinase inhibitors for the treatment of cancer | |
AR088235A1 (es) | Derivados de pirazoloquinolina | |
EA200970656A1 (ru) | Вич-ингибирующие 5,6-замещенные пиримидины | |
TN2012000608A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
AR076694A1 (es) | Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion | |
EP1627869A4 (en) | AMIDE DERIVATIVE | |
AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
WO2006040318A3 (en) | Pi3 kinase gamma inhibitors for the treatment of anaemia | |
FI3891145T3 (fi) | TREX1:n MODULAATTORIT | |
WO2010089510A3 (fr) | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique | |
RU2007126846A (ru) | Амидные соединения и активаторы рецептора тромбопоэтина | |
AR097756A1 (es) | Derivados de fenilalanina sustituidos | |
HK1142604A1 (en) | Quinolines and their therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |